Maria Jose J. F.
- Country
- Spain
- Department
- Oncology
Research Overview
- Pharmacokinetics Study Comparing GME751 and US/EU-Approved Pembrolizumab in Stage II and III Melanoma Patients Requiring Adjuvant Therapy
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- A Pharmacokinetic Comparison of JPB898 and Nivolumab in Patients with Resected Stage IIB, IIC, or III Melanoma in the Adjuvant Setting
Data & Insights
Has run more than one trial at 352 of 618 partner sites.
Specializations
Urological Oncology
The investigator specializes in treating advanced metastatic castration-resistant prostate cancer and muscle-invasive bladder cancer, conducting innovative therapeutic research using various treatment approaches.
- Novel combination therapies for prostate cancer
- Targeted therapies in urothelial carcinoma
- Advanced treatment protocols for bladder cancer
Expertise extends to evaluating new therapeutic agents and immunotherapy combinations for urological malignancies.
Melanoma Research
Focus on developing treatments for advanced and metastatic melanoma, particularly investigating novel immunotherapy combinations and targeted approaches for both resectable and unresectable disease.
- Immunotherapy combinations
- Neoadjuvant treatment strategies
- Therapeutic antibodies in melanoma
Specialized in evaluating innovative treatment modalities for various stages of melanoma.
Clinical Research Innovation
Active involvement in evaluating biosimilar therapeutics and developing personalized treatment approaches across multiple cancer types.
- Comparative effectiveness studies
- Novel drug delivery systems
- Biomarker-driven therapies
Emphasis on advancing precision medicine through clinical trials of targeted therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.